samedan logo
 
 
 
spacer
home > ebr > summer 2019 > fighting the global threat
PUBLICATIONS
European Biopharmaceutical Review

Fighting the Global Threat

The discovery of penicillin by Alexander Fleming in 1928 revolutionised medicine. This antibiotic soon became one of the most widely used in treating common bacterial infections, as well as pneumonia, tuberculosis, syphilis, and more (1). However, the Nobel Prize winner also predicted how an irresponsible use of penicillin could lead to the development of resistant bacteria, resulting in losing the antibiotic efficacy and death caused by a lack of alternative treatments. His concern has become a real-life scenario, affecting the medical sector and animal husbandry on a global scale.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Adrian Fellows has been involved in R&D − particularly in the fields of disinfection and infection control − since 1972. He has filed numerous successful patents in these areas and others, including thermal devices and chemical specialities. Adrian filed the first patent applications for disinfectant wipes in the early 1970s, led a multinational team in an EU framework R&D program, and was a visiting research fellow at Huddersfield University, UK. Since 2005, he has been R&D director for Gama Healthcare, which has become a leading presence in global infection control. More recently, Adrian has been involved in leading collaborative projects in developing novel means to combat AMR.
spacer
Adrian Fellows
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera to build state-of-the-art manufacturing facility in Poland to serve more customers and patients

Based in Szczecin, this facility extends Nemera’s manufacturing capabilities and will bring more drug delivery device solutions to patients. Following the dynamic growth of the drug delivery devices market, as a world leader, Nemera is thrilled to extend its manufacturing capabilities in Poland.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement